Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.
A dual-targeting CAR T therapy produces better survival outcomes than standard chemotherapy for advanced lymphoma, with fewer serious complications overall.
Anti-CD19 CAR T-cell therapy is the standard second-line treatment for patients with relapsed or refractory large B-cell lymphoma. Serious adverse events occurred in 31 (41%) patients with zamto-cel and 50 (66%) with R-GemOx, most commonly malignant neoplasm progression (11 [14%] and 38 [50%]), cytokine release syndrome (CRS; six [8%] and none), and immune effector cell-associated neurotoxicity syndrome (four [5%] and none).
What the study was
- Study design
- Randomized controlled trial
- Sample size
- 82
- Category
- Treatment Innovation
- Maturity
- Potentially Practice-Changing
- Journal
- Lancet Oncol
Why it surfaced
Randomized controlled trial; human evidence; PubMed abstract reviewed; conservative rubric score 9/10.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.